JAK1 and psoriasis: While some JAK inhibitors, including upadacitinib and abrocitinib, are marketed as being selective, there is evidence that JAK1 inhibitors interact with the JAK2/3 and tyrosine kinase pathways which results in blockade of a broader number of cytokines and explains JAK inhibitor’s ability to treat both psoriasis and AD.9